We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+18.22%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$495M
AUM Growth
+$97.7M
Cap. Flow
+$53.3M
Cap. Flow %
10.77%
Top 10 Hldgs %
75.85%
Holding
33
New
7
Increased
3
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$60M
2
KALA icon
KALA BIO
KALA
+$25.5M
3
VRNA
Verona Pharma
VRNA
+$10.4M
4
KDMN
Kadmon Holdings, Inc.
KDMN
+$9.52M
5
ZLAB icon
Zai Lab
ZLAB
+$9.06M

Top Sells

Rank Stock Value
1
CDXS icon
Codexis
CDXS
+$12.4M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$5.32M
3
DVAX
Dynavax Technologies
DVAX
+$3.47M
4
AKTX
Akari Therapeutics
AKTX
+$855K
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$258K

Sector Composition

Rank Sector Weight
1 Healthcare 92.89%
2 Materials 1.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKTX
26
Akari Therapeutics
AKTX
$14.9M
$2.12M 0.43%
432
-228
-35% -$855K
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$2.02M 0.41%
+300,325
New +$2.14M
VIRX
28
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$970K 0.2%
14,286
– –
SLNOW
29
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
$112K 0.02%
+188,772
New +$110K
DVAX
30
DELISTED
Dynavax Technologies
DVAX
– –
-359,827
Closed -$3.47M
CAPNW
31
DELISTED
Capnia, Inc. Series A Warrant
CAPNW
– –
-943,858
Closed -$159K
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Vivo Capital held 33 positions worth $495M, up 25% from $397M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Vivo Capital deployed $53.3M of net new capital in Q3 2017, opening 7 new positions and adding to 3 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 1,976,818 shares worth $73.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Codexis, an estimated $12.4M trimmed.

  • Vivo Capital's largest Q3 2017 buy was Biohaven Pharmaceutical Holding Company Ltd.: 1,976,818 shares worth $73.9M.
  • Vivo Capital added most to Verona Pharma in Q3 2017, an estimated $10.4M increase.
  • Vivo Capital's biggest Q3 2017 reduction was Codexis, cutting an estimated $12.4M.
  • Vivo Capital fully exited Dynavax Technologies in Q3 2017, selling an estimated $3.47M.
  • Vivo Capital's ten largest holdings make up 76% of its $495M portfolio in Q3 2017.
  • Vivo Capital opened 7 new positions and closed 4 in Q3 2017.
  • Vivo Capital's portfolio value rose 25% quarter-over-quarter to $495M.

Based on Vivo Capital's 13F filing for Q3 2017, filed 13 Nov 2017.